| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 697 0 |
 SM ISO690:2012GUNTHER, Gunar, ALEXANDRU, Sofia, BARBUŢĂ, Raisa, CIOBANU, Ana, KRUDU, V.. Clinical management of multidrug-resistant tuberculosis in 16 european countries. In: American Journal of Respiratory and Critical Care Medicine, 2018, nr. 3(198), pp. 379-386. ISSN 1073-449X. DOI: https://doi.org/10.1164/rccm.201710-2141OC |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
 American Journal of Respiratory and Critical Care Medicine |
|
| Numărul 3(198) / 2018 / ISSN 1073-449X | |
|
|
| DOI:https://doi.org/10.1164/rccm.201710-2141OC | |
| Pag. 379-386 | |
| Rezumat | |
Rationale: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. Objectives: To document the management and treatment outcome in patients with MDR-TB in Europe. Methods: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients with MDR-TB in Europe. Treatment outcomes were compared by World Health Organization and alternative simplified definitions by the Tuberculosis Network European Trialsgroup (TBNET). Measurements and Main Results: A total of 380 patients with MDR-TB were recruited and followed up between 2010 and 2014 in 16 European countries. Patients in high-incidence countries compared with low-incidence countries were treated more frequently with standardized regimen (83.2% vs. 9.9%), had delayed treatment initiation (median, 111 vs. 28 d), developed more additional drug resistance (23% vs. 5.8%), and had increased mortality (9.4% vs. 1.9%). Only 20.1% of patients using pyrazinamide had proven susceptibility to the drug. Applying World Health Organization outcome definitions, frequency of cure (38.7% vs. 9.7%) was higher in high-incidence countries. Simplified outcome definitions that include 1 year of follow-up after the end of treatment showed similar frequency of relapse-free cure in low- (58.3%), intermediate- (55.8%), and high-incidence (57.1%) countries, but highest frequency of failure in high-incidence countries (24.1% vs. 14.6%). Conclusions: Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected by World Health Organization outcome definitions. |
|
| Cuvinte-cheie Extensively drug-resistant TB, management, MDR-TB, Outcome definitions, TBNET |
|
|
Crossref XML Export
<?xml version='1.0' encoding='utf-8'?> <doi_batch version='4.3.7' xmlns='http://www.crossref.org/schema/4.3.7' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.crossref.org/schema/4.3.7 http://www.crossref.org/schema/deposit/crossref4.3.7.xsd'> <head> <doi_batch_id>ibn-65461</doi_batch_id> <timestamp>1714016113</timestamp> <depositor> <depositor_name>Information Society Development Instiute, Republic of Moldova</depositor_name> <email_address>idsi@asm.md</email_address> </depositor> </head> <body> <journal> <journal_metadata> <full_title>American Journal of Respiratory and Critical Care Medicine</full_title> <issn media_type='print'>1073449X</issn> </journal_metadata> <journal_issue> <publication_date media_type='print'> <year>2018</year> </publication_date> <issue>3(198)</issue> </journal_issue> <journal_article publication_type='full_text'><titles> <title>Clinical management of multidrug-resistant tuberculosis in 16 european countries</title> </titles> <contributors> <person_name sequence='first' contributor_role='author'> <given_name>Gunar</given_name> <surname>Gunther</surname> </person_name> <person_name sequence='additional' contributor_role='author'> <given_name>Sofia</given_name> <surname>Alexandru</surname> </person_name> <person_name sequence='additional' contributor_role='author'> <given_name>Raisa</given_name> <surname>Barbuţă</surname> </person_name> <person_name sequence='additional' contributor_role='author'> <given_name>Ana</given_name> <surname>Ciobanu</surname> </person_name> <person_name sequence='additional' contributor_role='author'> <given_name>Valeriu</given_name> <surname>Crudu</surname> </person_name> </contributors> <publication_date media_type='print'> <year>2018</year> </publication_date> <pages> <first_page>379</first_page> <last_page>386</last_page> </pages> <doi_data> <doi>10.1164/rccm.201710-2141OC</doi> <resource>http://www.crossref.org/</resource> </doi_data> </journal_article> </journal> </body> </doi_batch>
|
|
|
